04:52 PM EDT, 09/29/2025 (MT Newswires) -- Kura Oncology ( KURA ) and Kyowa Kirin said late Monday the first patient has been dosed under the KOMET-017 trial protocol to test ziftomenib in patients with frontline acute myeloid leukemia trial.

The protocol comprises two phase 3 trials to evaluate the drug candidate in combination with both intensive and non-intensive combination regimens, the companies said, adding that the trial would enroll patients at up to 200 sites worldwide.